MedTrace Logo

Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments

NCT07618377 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-07-20

No results posted yet for this study

Summary

To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies

Conditions

Interventions

DRUG

DCC-2618

DCC-2618 150 mg, administered orally once daily

Sponsors & Collaborators

Principal Investigators

  • Project Leader · Ono Pharmaceutical Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-07
Primary Completion
2028-02-29
Completion
2028-02-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07618377 on ClinicalTrials.gov